Epigenetic agents in combined anticancer therapy

被引：16

作者：

Kejik, Zdenek ^{[1
]}

Jakubek, Milan ^{[2
,3
]}

Kaplanek, Robert ^{[2
,3
]}

Kralova, Jarmila ^{[1
]}

Mikula, Ivan ^{[1
]}

Martasek, Pavel ^{[2
]}

Kral, Vladimir ^{[1
,2
,3
]}

机构：

[1] Charles Univ Prague, Fac Med 1, Katerinska 32, Prague 12108 2, Czech Republic

[2] Charles Univ Prague, Fac Med 1, BIOCEV, Vestec 25250, Czech Republic

[3] Univ Chem & Technol, Fac Chem Engn, Dept Analyt Chem, Tech 5, Prague 16628 6, Czech Republic

来源：

FUTURE MEDICINAL CHEMISTRY | 2018年 / 10卷 / 09期

关键词：

anticancer treatment; combination therapy; epigenetic agents; HISTONE DEACETYLASE INHIBITOR; CELL LUNG-CANCER; SUBEROYLANILIDE HYDROXAMIC ACID; DNA METHYLATION; VALPROIC ACID; BREAST-CANCER; SYNERGISTIC COMBINATION; ONCOLYTIC ADENOVIRUS; ANTITUMOR EFFICACY; INDUCED APOPTOSIS;

D O I：

10.4155/fmc-2017-0203

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In the last decade, epigenetic drugs (such as inhibitors of DNA methyltransferases and histone deacetylases) have been intensively used for cancer treatment. Their applications have shown high anticancer effectivity and tolerable side effects. However, they are unfortunately not effective in the treatment of some types and phenotypes of cancers. Nevertheless, several studies have demonstrated that problems of drug efficacy can be overcome through the combined application of therapeutic modulates. Therefore, combined applications of epigenetic agents with chemotherapy, radiation therapy, immunotherapy, oncolytic virotherapy and hyperthermia have been presented. This review summarizes and discusses the general principles of this approach, as introduced and supported by numerous examples. In addition, predictions of the future potential applications of this methodology are included.

引用

页码：1113 / 1130

页数：18

共 133 条

[1] Adjuvant Therapy for Melanoma [J].

Agha, Aya ;

Tarhini, Ahmad A. .

CURRENT ONCOLOGY REPORTS, 2017, 19 (05)

[2] Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine [J].

Ahrens, Theresa D. ;

Timme, Sylvia ;

Hoeppner, Jens ;

Ostendorp, Jenny ;

Hembach, Sina ;

Follo, Marie ;

Hopt, Ulrich T. ;

Werner, Martin ;

Busch, Hauke ;

Boerries, Melanie ;

Lassmann, Silke .

EPIGENETICS, 2015, 10 (05) :431-445

[3] Modulation of Epigenetic Targets for Anticancer Therapy: Clinicopathological Relevance, Structural Data and Drug Discovery Perspectives [J].

Andreoli, Federico ;

Barbosa, Armenio Jorge Moura ;

Parenti, Marco Daniele ;

Del Rio, Alberto .

CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (04) :578-613

[4] Genomic DNA Hypomethylation by Histone Deacetylase Inhibition Implicates DNMT1 Nuclear Dynamics [J].

Arzenani, Mohsen Karimi ;

Zade, Atosa Esteki ;

Ming, Yu ;

Vijverberg, Susanne J. H. ;

Zhang, Zhe ;

Khan, Zahidul ;

Sadique, Syed ;

Kallenbach, Lorenz ;

Hu, LiFu ;

Vukojevic, Vladana ;

Ekstrom, Tomas J. .

MOLECULAR AND CELLULAR BIOLOGY, 2011, 31 (19) :4119-4128

[5] Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines [J].

Asgar, Md. Ali ;

Senawong, Gulsiri ;

Sripa, Banchob ;

Senawong, Thanaset .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 48 (01) :409-420

[6] Nonantibiotic Effects of Fluoroquinolones in Mammalian Cells [J].

Badal, Sujan ;

Her, Yeng F. ;

Maher, L. James, III .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (36) :22287-22297

[7] Iron Overload during Follow-up after Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma [J].

Bae, Soo Jin ;

Kang, Christine ;

Sung, Ki Woong ;

Chueh, Hee Won ;

Son, Meong Hi ;

Lee, Soo Hyun ;

Yoo, Keon Hee ;

Koo, Hong Hoe .

JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (04) :363-369

[8] Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma [J].

Bai, Xueli ;

Wu, Lihua ;

Liang, TingBo ;

Liu, ZhiQiang ;

Li, JunJian ;

Li, DongLin ;

Xie, HaiYang ;

Yin, ShengYong ;

Yu, Jun ;

Lin, Qi ;

Zheng, ShuSen .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (01) :83-91

[9] Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line [J].

Baldan, Federica ;

Mio, Catia ;

Allegri, Lorenzo ;

Puppin, Cinzia ;

Russo, Diego ;

Filetti, Sebastiano ;

Damante, Giuseppe .

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2015, 2015

[10] Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non-Small Cell Lung Carcinoma Cells [J].

Bar, Jair ;

Hasim, Mohamed S. ;

Baghai, Tabassom ;

Niknejad, Nima ;

Perkins, Theodore J. ;

Stewart, David J. ;

Sekhon, Harmanjatinder S. ;

Villeneuve, Patrick J. ;

Dimitroulakos, Jim .

NEOPLASIA, 2016, 18 (09) :525-535

← 1 2 3 4 5 6 7 8 9 10 →